

FOURTH NATIONAL REPORT UNDER THE CARTAGENA PROTOCOL ON BIOSAFETY

Origin of the report


1. Country: [State of Palestine]
- Contact person submitting the report*
2. Name: [Mohamad Mahassneh]
3. Title: [CBD national Focal Point and Director of Biodiversity & Protected Areas Dept.]
4. Organization: [Environment Quality Authority (EQA)]
5. Mailing address: Environment Quality Authority (EQA), Ramallah-Palestine-Sharafeh-Jenan St.
6. Telephone: +970-22403495
7. Fax: +970-22403494
8. E-mail: mahassneh2000@yahoo.com
9. Organizations/stakeholders who were consulted or participated in the preparation of this report: **EQA-Dr. Issa Adwan-Director General of Environmental Resources Directorate, Mohammad Mahassneh,-CBD Focal point and Director of Biodiversity Dept. Dr. Omar Darissa-Consultant for Preparing the National Biosafety Framework-PhD., UNESCO BIOTECHNOLOGY CENTER**

Submission

10. Date of submission: [31 / 08 /2021]
11. Time period covered by this report: From [NOV / 2020 to - AUG -2021]

Signature of the reporting officer¹

Mohammad Mahassneh



- | | |
|-----------------------------------------------------------------------------------------------|------------------------------|
| 12. If your country is not a Party to the Cartagena Protocol on Biosafety (CPB), is there any | <input type="checkbox"/> Yes |
|-----------------------------------------------------------------------------------------------|------------------------------|

¹ This document is a protected form in MS Word format to enable further processing of the information contained therein by the CBD Secretariat. Only text entries and checkboxes may be changed. Once you finish filling in the form, please save it and print this first page for signature. This form is also available in the BCH for electronic submission at:

<https://beta.bch.cbd.int/register/NR4>

IMPORTANT: To facilitate the analysis of the information contained in this report, it is recommended that Parties submit the report online through the Biosafety Clearing-House or as an attachment to an e-mail in MS Word format, together with a scanned copy of the signed first page, to the Secretariat at: secretariat@cbd.int.

Please do not send this report via fax or postal mail or in electronic formats other than MS Word.

national process in place towards becoming a Party?	<input type="checkbox"/> No
<p>13. Here you may provide further details: Palestine is a Party to the CPB. since April 2015</p>	
<p>Article 2 – General provisions <i>Article 2 requires each Party to take the necessary and appropriate legal, administrative and other measures to implement its obligations under the Protocol</i></p>	
<p>14. Has your country introduced the necessary national measures for the implementation of the Protocol?</p>	<input type="checkbox"/> National measures are fully in place <input checked="" type="checkbox"/> National measures are partially in place <input type="checkbox"/> Only temporary measures have been introduced <input checked="" type="checkbox"/> Only draft measures exist <input type="checkbox"/> No measures have yet been taken
<p>15. Which specific instruments are in place for the implementation of national biosafety measures?</p>	<input type="checkbox"/> One or more national biosafety laws <input type="checkbox"/> One or more national biosafety regulations <input type="checkbox"/> One or more sets of biosafety guidelines <input checked="" type="checkbox"/> Other laws, regulations or guidelines that indirectly apply to biosafety <input type="checkbox"/> No instruments are in place
<p>16. Has your country undertaken initiatives to mainstream biosafety into national biodiversity strategies and action plans, other policies, or legislation?</p>	<input checked="" type="checkbox"/> Yes: [In the NBSAP] <input type="checkbox"/> No <input type="checkbox"/> Other: Mainstream strategies have been proposed in the NBF
<p>17. Has your country established a mechanism for budget allocations for the operation of its national biosafety measures?</p>	<input type="checkbox"/> Yes <input type="checkbox"/> Yes, to some extent: [Please specify] <input checked="" type="checkbox"/> No
<p>18. Does your country have permanent staff to administer functions directly related to biosafety?</p>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<p>19. If you answered <i>Yes</i> to question 18, how many permanent staff members are in place whose functions are directly related to biosafety ?</p>	<input type="checkbox"/> 1 to 4 <input type="checkbox"/> 5 to 9 <input type="checkbox"/> 10 or more <i>Is this number adequate:</i> <input type="checkbox"/> Yes <input type="checkbox"/> No
<p>20. Here you may provide further details on the implementation of Article 2 in your country: The existing Palestinian By-laws, regulations and legislations that indirectly apply to biosafety have been surveyed, identified and summarized in the Palestinian national framework for biosafety (NBF) which is</p>	

almost in the final stage of completion.

Article 5 – Pharmaceuticals

- | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| 21. Does your country regulate the transboundary movement, handling or use of living modified organisms (LMOs) which are pharmaceuticals to humans? | <input type="checkbox"/> Yes
<input type="checkbox"/> Yes, to some extent: [Please specify]
<input checked="" type="checkbox"/> No |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|

22. Here you may provide further details on the implementation of Article 5 in your country:

There are no biosafety regulations for the transboundary movement, handling or use of LMOs which are pharmaceuticals to humans. However, a Draft Action Plan for the development of Biotechnology and Biosafety policy in Palestine has been proposed in the NBF. In statement 5 of this policy, the government has to facilitate the investments leading to broader application and commercialization of modern biotechnology including pharmaceuticals. Meanwhile, the existing biosafety regulations for GMOs/LMOs and products thereof apply to pharmaceuticals derived from LMOs. If extra biosafety regulations for this purpose are to be needed, they shall be established in cooperation with the related stakeholders, mainly the Ministry of Health.

Article 6 – Transit and contained use

- | | |
|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| 23. Does your country regulate the transit of LMOs? | <input type="checkbox"/> Yes
<input type="checkbox"/> Yes, to some extent: [Please specify]
<input checked="" type="checkbox"/> No |
|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|

- | | |
|-----------------------------------------------------------|------------------------------------------------------------------------|
| 24. Does your country regulate the contained use of LMOs? | <input type="checkbox"/> Yes
<input checked="" type="checkbox"/> No |
|-----------------------------------------------------------|------------------------------------------------------------------------|

- | | |
|----------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| 25. Has your country taken a decision concerning the import of LMOs for contained use? | <input type="checkbox"/> Yes
<input checked="" type="checkbox"/> No |
|----------------------------------------------------------------------------------------|------------------------------------------------------------------------|

26. Here you may provide further details on the implementation of Article 6 in your country:

The country has not encountered cases related to the transit or contained uses of LMOs yet. However, regulation mechanisms for such cases have been proposed in the developing Palestinian NBF.

Articles 7 to 10: Advance informed agreement (AIA) and intentional introduction of LMOs into the environment

- | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| 27. Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure? | <input type="checkbox"/> Yes
<input type="checkbox"/> Yes, to some extent: [Please specify]
<input checked="" type="checkbox"/> No |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|

- | | |
|-------------------------------------------------------------------------------------------------|------------------------------|
| 28. When acting as the Party of export, has your country established legal requirements for the | <input type="checkbox"/> Yes |
|-------------------------------------------------------------------------------------------------|------------------------------|

<p>accuracy of information contained in the notification provided by the exporter?</p>	<p><input type="checkbox"/> Yes, to some extent: [Please specify] <input type="checkbox"/> No <input checked="" type="checkbox"/> Not applicable (Party currently not exporting LMOs)</p>
<p>29. In the current reporting period, has your country received a notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>30. If you answered <i>Yes</i> to question 29, did the notification(s) contain complete information (at a minimum the information specified in Annex I to the Cartagena Protocol on Biosafety)?</p>	<p><input type="checkbox"/> Yes, always <input type="checkbox"/> In some cases only <input type="checkbox"/> No</p>
<p>31. If you answered <i>Yes</i> to question 29, has your country acknowledged receipt of the notification(s) to the notifier within ninety days of receipt?</p>	<p><input type="checkbox"/> Yes, always <input type="checkbox"/> In some cases only <input type="checkbox"/> No</p>
<p>32. If you answered <i>Yes</i> to question 29, has your country informed of its decision(s):</p> <p>a. The notifier?</p> <p>b. The Biosafety Clearing-House (BCH)?</p>	<p><input type="checkbox"/> Yes, always <input type="checkbox"/> In some cases only <input type="checkbox"/> No</p> <hr/> <p><input type="checkbox"/> Yes, always <input type="checkbox"/> In some cases only <input type="checkbox"/> No</p>
<p>33. In the current reporting period, has your country taken a decision in response to the notification(s) regarding intentional transboundary movements of LMOs for intentional introduction into the environment?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>34. If you answered <i>Yes</i> to question 33, how many LMOs has your country approved for import for intentional introduction into the environment?</p>	<p><input type="checkbox"/> None <input type="checkbox"/> 1 to 4 <input type="checkbox"/> 5 to 9 <input type="checkbox"/> 10 or more</p>
<p>35. If you answered <i>under question 34</i> that <i>LMOs were approved</i>, have all these LMOs actually been imported into your country?</p>	<p><input type="checkbox"/> Yes, always <input type="checkbox"/> In some cases only <input type="checkbox"/> No</p>
<p>36. If you answered <i>Yes</i> to question 33, what percentage of your country's decisions fall into</p>	<p>[%] Approval of the import/use of the LMO(s)</p>

the following categories?	<p>without conditions</p> <p>[%] Approval of the import/use of the LMO(s) with conditions</p> <p>[%] Prohibition of the import/use of the LMO(s)</p> <p>[%] Request for additional relevant information</p> <p>[%] Inform the notifier that the period for communicating the decision has been extended</p>
37. If you answered <i>under question 36</i> that your country has taken a decision to <i>approve the import with conditions</i> or to <i>prohibit the import</i> , were the reasons provided?	<p><input type="checkbox"/> Yes, always</p> <p><input type="checkbox"/> In some cases only</p> <p><input type="checkbox"/> No</p>
<p>38. Here you may provide further details on the implementation of Articles 7 to 10 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs for intentional introduction to the environment:</p> <p>Palestine has not yet officially approved the import of GMOs/LMOs for any purpose.</p>	
<p>Article 11 – Procedure for living modified organisms intended for direct use as food or feed, or for processing (LMOs-FFP)</p>	
39. Does your country have law(s), regulation(s) or administrative measures for decision-making regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing?	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p>
40. Has your country established legal requirements for the accuracy of information to be provided by the applicant regarding the domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing?	<p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> Yes, to some extent: [Please specify]</p> <p><input checked="" type="checkbox"/> No</p>
41. In the current reporting period, how many decisions has your country taken <u>regarding domestic use</u> , including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing?	<p><input checked="" type="checkbox"/> None</p> <p><input type="checkbox"/> 1 to 4</p> <p><input type="checkbox"/> 5 to 9</p> <p><input type="checkbox"/> 10 or more</p>
42. Does your country have law(s), regulation(s) or administrative measures for decision-making regarding the import of LMOs for direct use as food or feed, or for processing?	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p>
43. In the current reporting period, how many decisions has your country taken <u>regarding the import</u> of LMOs for direct use as food or feed,	<p><input checked="" type="checkbox"/> None</p> <p><input type="checkbox"/> 1 to 4</p>

<p>or for processing?</p>	<p><input type="checkbox"/> 5 to 9 <input type="checkbox"/> 10 or more</p>
<p>44. Here you may provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing:</p> <p>The regulation for the implementation of Article 11 is proposed in the NBF. An administrative system has been proposed by the EQA including the National Biosafety Committee. In cases of inadequate scientific certainty on potential adverse effects of LMOs, it will not be allowed for transboundary movement or for direct uses as food, feed, or processing.</p>	
<p>Article 12 – Review of decision</p>	
<p>45. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> Yes, to some extent: [proposed] <input type="checkbox"/> No</p>
<p>46. In the current reporting period, has your country reviewed and/or changed a decision regarding an intentional transboundary movement of an LMO?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>47. If you answered <i>Yes</i> to question 46, how many decisions were reviewed and/or changed?</p>	<p><input type="checkbox"/> 1 to 4 <input type="checkbox"/> 5 to 9 <input type="checkbox"/> 10 or more</p>
<p>48. If you answered <i>Yes</i> to question 46, were any of the reviews triggered by a request from the Party of export or the notifier?</p>	<p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>49. If you answered <i>Yes</i> to question 48, did your country provide a response within ninety days setting out the reasons for the decision?</p>	<p><input type="checkbox"/> Yes, always <input type="checkbox"/> In some cases only <input type="checkbox"/> No</p>
<p>50. If you answered <i>Yes</i> to question 46, were any of the reviews initiated by your country as the Party of import?</p>	<p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>51. If you answered <i>Yes</i> to question 50, did your country, within thirty days, set out the reasons for the decision and inform:</p> <p>a. The notifier?</p> <p><input type="checkbox"/> Yes, always <input type="checkbox"/> In some cases only <input type="checkbox"/> No</p> <hr/> <p>b. The BCH?</p> <p><input type="checkbox"/> Yes, always <input type="checkbox"/> In some cases only <input type="checkbox"/> No</p>	

52. Here you may provide further details on the implementation of Article 12 in your country: No decisions have been made yet. But a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs are covered in the proposed bylaw on biosafety under Article 3.	
Article 13 – Simplified procedure	
53. Has your country established a mechanism for the application of the simplified procedure regarding an intentional transboundary movement of LMOs?	<input type="checkbox"/> Yes <input type="checkbox"/> Yes, to some extent: [Please specify] <input checked="" type="checkbox"/> No
54. In the current reporting period, has your country applied the simplified procedure?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
55. If you answered <i>Yes</i> to question 54, for how many LMOs has your country applied the simplified procedure?	<input type="checkbox"/> None <input type="checkbox"/> 1 to 5 <input type="checkbox"/> 5 or more
56. If you answered <i>Yes</i> to question 54, has your country informed the Parties through the BCH of the cases where the simplified procedure was applied?	<input type="checkbox"/> Yes, always <input type="checkbox"/> In some cases only <input type="checkbox"/> No
57. Here you may provide further details on the implementation of Article 13 in your country: No simplified procedures are established since it is planned that all applications must follow the proposed path of approval process for the decision-making.	
Article 14 – Bilateral, regional and multilateral agreements and arrangements	
58. How many bilateral, regional or multilateral agreements or arrangements relevant to biosafety has your country established with other Parties/non-Parties?	<input checked="" type="checkbox"/> None <input type="checkbox"/> 1 to 4 <input type="checkbox"/> 5 to 9 <input type="checkbox"/> 10 or more
59. If you answered <i>under question 58 that agreements or arrangements were established</i> , please provide a brief description of their scope and objective: [Type your text here]	
60. Here you may provide further details on the implementation of Article 14 in your country: Such agreements are welcomed upon the implementation of NBF in Palestine.	
Articles 15 & 16 – Risk assessment and risk management	
61. Does the domestic regulatory framework of your country require risk assessments of LMOs to be conducted?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
62. If you answered <i>Yes</i> to question 61, with	<input checked="" type="checkbox"/> For imports of LMOs for intentional

<p>regard to which LMOs does the requirement apply (select all that apply)?</p>	<p>introduction into the environment</p> <p><input checked="" type="checkbox"/> For imports of LMOs intended for direct use as food or feed, or for processing</p> <p><input checked="" type="checkbox"/> For decisions regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movements for direct use as food or feed, or for processing</p> <p><input checked="" type="checkbox"/> For imports of LMOs for contained use</p> <p><input type="checkbox"/> Other: [Please specify]</p>
<p>63. Has your country established a mechanism to conduct risk assessments prior to taking decisions regarding LMOs?</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> Yes, to some extent: proposed The NBF provide the outline to establish such mechanism.</p> <p><input type="checkbox"/> No</p>
<p>64. If you answered <i>Yes</i> to question 63, does the mechanism include procedures to identify and/or train national experts to conduct risk assessments?</p>	<p><input checked="" type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p>
<p><i>Capacity-building in risk assessment or risk management</i></p>	
<p>65. How many people in your country have been trained in risk assessment, risk management and monitoring of LMOs?</p> <p>a. Risk assessment:</p> <p><input checked="" type="checkbox"/> None</p> <p><input type="checkbox"/> 1 to 9</p> <p><input type="checkbox"/> 10 to 49</p> <p><input type="checkbox"/> 50 to 99</p> <p><input type="checkbox"/> 100 or more</p> <p><i>Is this number adequate:</i> <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <hr/> <p>b. Risk management:</p> <p><input checked="" type="checkbox"/> None</p> <p><input type="checkbox"/> 1 to 9</p> <p><input type="checkbox"/> 10 to 49</p> <p><input type="checkbox"/> 50 to 99</p> <p><input type="checkbox"/> 100 or more</p> <p><i>Is this number adequate:</i> <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <hr/> <p>c. Monitoring:</p> <p><input checked="" type="checkbox"/> None</p> <p><input type="checkbox"/> 1 to 9</p> <p><input type="checkbox"/> 10 to 49</p> <p><input type="checkbox"/> 50 to 99</p>	

	<input type="checkbox"/> 100 or more <i>Is this number adequate:</i> <input type="checkbox"/> Yes <input type="checkbox"/> No
66. Is your country using training material and/or technical guidance for training in risk assessment and risk management of LMOs?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
67. If you answered <i>Yes</i> to question 66, is your country using the “Manual on Risk Assessment of LMOs” (developed by the CBD Secretariat) for training in risk assessment?	<input type="checkbox"/> Yes <input type="checkbox"/> No
68. If you answered <i>Yes</i> to question 66, is your country using the “Guidance on Risk Assessment of LMOs” (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for training in risk assessment?	<input type="checkbox"/> Yes <input type="checkbox"/> No
69. Does your country have specific needs for further guidance on specific topics of risk assessment of LMOs?	<input checked="" type="checkbox"/> Yes: Proposed in NBF Palestine needs to identify national experts in risk assessment and risk management, if any. Otherwise, cooperation with other countries to acquire the expertise is a must. <input type="checkbox"/> No
70. Does your country have the capacity to detect, identify, assess the risk of and/or monitor LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health?	
a. Detect:	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
b. Identify:	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
c. Assess the risk:	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
d. Monitor:	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<i>Conducting risk assessment or risk management</i>	
71. Has your country adopted or used any guidance documents for the purpose of conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers?	
a. Risk assessment:	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

<p>b. Risk management:</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>72. If you answered <i>Yes</i> to question 71, is your country using the “Guidance on Risk Assessment of LMOs” (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers?</p>	<p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>73. Has your country adopted common approaches or methodologies to risk assessment in coordination with other countries?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>74. Has your country cooperated with other Parties with a view to identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>75. In the current reporting period, has your country conducted any kind of risk assessment of LMOs, including for contained use, field trials, commercial purposes, direct use as food, feed, or for processing?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>76. If you answered <i>Yes</i> to question 75, how many risk assessments were conducted?</p>	<p><input type="checkbox"/> 1 to 9 <input type="checkbox"/> 10 to 49 <input type="checkbox"/> 50 to 99 <input type="checkbox"/> More than 100</p>
<p>77. If you answered <i>Yes</i> to question 75, please indicate the scope of the risk assessments (select all that apply):</p>	<p><input type="checkbox"/> LMOs for contained use (in accordance with Article 3) <input type="checkbox"/> LMOs for intentional introduction into the environment for experimental testing or field trials <input type="checkbox"/> LMOs for intentional introduction into the environment for commercial purposes <input type="checkbox"/> LMOs for direct use as food <input type="checkbox"/> LMOs for direct use as feed <input type="checkbox"/> LMOs for processing <input type="checkbox"/> Other: [Please specify]</p>
<p>78. If you answered <i>Yes</i> to question 75, were risk assessments conducted for all decisions taken on LMOs for intentional introduction into the environment or on domestic use of LMOs that may be subject to transboundary movement</p>	<p><input type="checkbox"/> Yes, always <input type="checkbox"/> In some cases only <input type="checkbox"/> No</p>

for direct use as food or feed, or for processing?	
79. Has your country established appropriate mechanisms, measures and strategies to regulate and manage risks identified in the risk assessment of LMOs?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
80. Has your country taken appropriate measures to prevent unintentional transboundary movements of LMOs, including such measures as requiring a risk assessment to be carried out prior to the first release of a LMO?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
81. Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use?	<input type="checkbox"/> Yes <input type="checkbox"/> Yes, to some extent: [Please specify] <input checked="" type="checkbox"/> No
82. Has your country established a mechanism for monitoring potential effects of LMOs released into the environment?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> Yes, to some extent: proposed in the NBF <input type="checkbox"/> No
83. Does your country have the necessary infrastructure (e.g. laboratory facilities) for monitoring or managing LMOs?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
84. Here you may provide further details on the implementation of Articles 15 and 16 in your country: The mechanisms for conducting risk assessment and risk management have been proposed in the NBF. No application for risk assessment or risk management had been received.	
Article 17 – Unintentional transboundary movements² and emergency measures	
85. Has your country established measures to notify affected or potentially affected States, the Biosafety Clearing-House and, where appropriate, relevant international organizations in case of a release under its jurisdiction that leads, or may lead, to an unintentional transboundary movement?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> Yes, to some extent: proposed measures in the NBF <input type="checkbox"/> No
86. In the current reporting period, how many releases of LMOs occurred under your country's jurisdiction that led, or may have led, to an unintentional transboundary	<input checked="" type="checkbox"/> None <input type="checkbox"/> 1 to 4

² In accordance with the operational definition adopted in decision CP-VIII/16, “‘Unintentional transboundary movement’ is a transboundary movement of a living modified organism that has inadvertently crossed the national borders of a Party where the living modified organism was released, and the requirements of Article 17 of the Protocol apply to such transboundary movements only if the living modified organism involved is likely to have significant adverse effects on the conservation and sustainable use of biological diversity, taking also into account risks to human health, in the affected or potentially affected States.”

movement?	<input type="checkbox"/> 5 to 9 <input type="checkbox"/> 10 or more
87. If you answered <i>under question 86</i> that a <i>release occurred</i> , has your country notified affected or potentially affected States, the Biosafety Clearing-House and, where appropriate, relevant international organizations?	<input type="checkbox"/> Yes, always <input type="checkbox"/> In some cases only <input type="checkbox"/> No
88. Does your country have the capacity to take appropriate response measures in response to unintentional transboundary movements?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
89. In the current reporting period, how many times has your country become aware of an unintentional transboundary movement into its territory?	<input checked="" type="checkbox"/> None <input type="checkbox"/> 1 to 4 <input type="checkbox"/> 5 to 9 <input type="checkbox"/> 10 or more
90. Here you may provide further details on the implementation of Article 17 in your country: EQA is the contact authority in cases of unintentional transboundary movements. There contact information as well the proposed emergency measures will be submitted to the BCH upon getting an access.	

Article 18 – Handling, transport, packaging and identification

91. Has your country taken measures to require that <i>LMOs that are subject to transboundary movement</i> are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> Yes, to some extent: Proposed in the NBF <input type="checkbox"/> No
92. Has your country taken measures to require that documentation accompanying LMOs-FFP, <i>in cases where the identity of the LMOs is not known</i> , clearly identifies that they <i>may contain LMOs</i> and are not intended for intentional introduction into the environment, as well as a contact point for further information?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> Yes, to some extent: Proposed in the NBF <input type="checkbox"/> No
93. Has your country taken measures to require that documentation accompanying LMOs-FFP, <i>in cases where the identity of the LMOs is known</i> , clearly identifies that they <i>contain LMOs</i> and are not intended for intentional introduction into the environment, as well as a contact point for further information?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> Yes, to some extent: Proposed in the NBF <input type="checkbox"/> No
94. If you answered <i>Yes</i> to question(s) 91, 92 and/or 93, what type of documentation	<input checked="" type="checkbox"/> Documentation specific for LMOs <input type="checkbox"/> As part of other documentation (not specific for

accompanying LMOs does your country require?	<input type="checkbox"/> LMOs) <input type="checkbox"/> Other: [Please specify]
95. Has your country taken measures to require that documentation accompanying <i>LMOs that are destined for contained use</i> clearly identifies them as <i>LMOs</i> and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> Yes, to some extent: Proposed in the NBF <input type="checkbox"/> No
96. If you answered <i>Yes</i> to question 95, what type of documentation does your country require for the identification of LMOs that are destined for contained use?	<input checked="" type="checkbox"/> Documentation specific for LMOs <input type="checkbox"/> As part of other documentation (not specific for LMOs) <input type="checkbox"/> Other: [Please specify]
97. Has your country taken measures to require that documentation accompanying <i>LMOs that are intended for intentional introduction into the environment of the Party of import</i> , clearly identifies them as <i>living modified organisms</i> ; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> Yes, to some extent: Proposed in the NBF <input type="checkbox"/> No
98. If you answered <i>Yes</i> to question 97, what type of documentation does your country require for the identification of LMOs that are intended for intentional introduction into the environment?	<input checked="" type="checkbox"/> Documentation specific for LMOs <input type="checkbox"/> As part of other documentation (not specific for LMOs) <input type="checkbox"/> Other: [Please specify]
99. Does your country have available any guidance for the purpose of ensuring the safe handling, transport, and packaging of living modified organisms?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
100. Does your country have the capacity to enforce the requirements of identification and documentation of LMOs?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> Yes, to some extent: Proposed in the NBF <input type="checkbox"/> No
101. How many customs officers in your country have received training in the identification of LMOs?	<input checked="" type="checkbox"/> None <input type="checkbox"/> 1 to 9 <input type="checkbox"/> 10 to 49

	<input type="checkbox"/> 50 to 99 <input type="checkbox"/> 100 or more <i>Is this number adequate:</i> <input type="checkbox"/> Yes <input type="checkbox"/> No
102. Has your country established procedures for the sampling and detection of LMOs?	<input type="checkbox"/> Yes <input type="checkbox"/> Yes, to some extent: [Please specify] <input checked="" type="checkbox"/> No
103. How many laboratory personnel in your country have received training in detection of LMOs?	<input checked="" type="checkbox"/> None <input type="checkbox"/> 1 to 9 <input type="checkbox"/> 10 to 49 <input type="checkbox"/> 50 to 99 <input type="checkbox"/> 100 or more <i>Is this number adequate:</i> <input type="checkbox"/> Yes <input type="checkbox"/> No
104. Does your country have reliable access to laboratory facilities for the detection of LMOs?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
105. How many laboratories in your country are certified for LMO detection?	<input checked="" type="checkbox"/> None <input type="checkbox"/> 1 to 4 <input type="checkbox"/> 5 to 9 <input type="checkbox"/> 10 to 49 <input type="checkbox"/> 50 or more
106. If you answered <i>under question 105</i> that <i>certified laboratories exist in your country</i> , how many of them are currently operating in the detection of LMOs?	<input type="checkbox"/> None <input type="checkbox"/> 1 to 4 <input type="checkbox"/> 5 to 9 <input type="checkbox"/> 10 to 49 <input type="checkbox"/> 50 or more
107. Here you may provide further details on the implementation of Article 18 in your country: Biosafety regulations, policies, bi-law proposed in the NBF include the import of GMOs and products thereof. Any importing party must follow the procedures and standards for safe handling and packing of GM materials. A record of all local or international movements of GMOs/LMOs and products thereof must be kept. The EQA and NBC shall be informed about all movements, usage, and storage of GMOs/LMOs. Sampling and detection methods and facilities shall be installed.	
Article 19 – Competent national authorities and national focal points	
108. In case your country has designated more than one competent national authority, has your country established a mechanism for the coordination of their actions prior to taking decisions regarding LMOs?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> Not applicable (no competent national authority was designated)

	<input type="checkbox"/> Not applicable (only one competent national authority was designated)
<p>109. Has your country established adequate institutional capacity to enable the competent national authority(ies) to perform the administrative functions required by the Cartagena Protocol on Biosafety?</p>	<input type="checkbox"/> Yes <input type="checkbox"/> Yes, to some extent: [Please specify] <input checked="" type="checkbox"/> No
<p>110. Has your country undertaken initiatives to strengthen collaboration among national focal points, competent national authority(ies) and other institutions on biosafety-related matters?</p>	<input type="checkbox"/> Yes: [Please specify] <input checked="" type="checkbox"/> No
<p>111. Here you may provide further details on the implementation of Article 19 in your country: A member of the EQA, is responsible for the coordination of the focal point activities. Competent national authorities including the ministries of agriculture and health as well as academic and research institutions have participated in developing the NBF through participation in the biosafety workshops, response to surveys, and being part of the NBC.</p>	
<p>Article 20 – Information sharing and the Biosafety Clearing-House (BCH)</p>	
<p>112. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH.</p>	
<p>a. Existing legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3 (a))</p>	<input type="checkbox"/> Information available and in the BCH <input checked="" type="checkbox"/> Information available but not in the BCH <input type="checkbox"/> Information available but only partially available in the BCH <input type="checkbox"/> Information not available
<p>b. Legislation, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5)</p>	<input type="checkbox"/> Information available and in the BCH <input checked="" type="checkbox"/> Information available but not in the BCH <input type="checkbox"/> Information available but only partially available in the BCH <input type="checkbox"/> Information not available
<p>c. Bilateral, multilateral and regional agreements and arrangements (Article 14, paragraph 2, and Article 20, paragraph 3 (b))</p>	<input type="checkbox"/> Information available and in the BCH <input type="checkbox"/> Information available but not in the BCH <input type="checkbox"/> Information available but only partially available in the BCH <input checked="" type="checkbox"/> Information not available
<p>d. Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17,</p>	<input type="checkbox"/> Information available and in the BCH <input checked="" type="checkbox"/> Information available but not in the BCH <input type="checkbox"/> Information available but only partially

<p>paragraph 3 (e))</p>	<p>available in the BCH</p> <p><input type="checkbox"/> Information not available</p>
<p>e. Decisions by a Party regarding transit of LMOs (Article 6, paragraph 1)</p>	<p><input type="checkbox"/> Information available and in the BCH</p> <p><input type="checkbox"/> Information available but not in the BCH</p> <p><input type="checkbox"/> Information available but only partially available in the BCH</p> <p><input checked="" type="checkbox"/> Information not available</p>
<p>f. Decisions by a Party regarding import of LMOs for contained use (Article 6, paragraph 2)</p>	<p><input type="checkbox"/> Information available and in the BCH</p> <p><input type="checkbox"/> Information available but not in the BCH</p> <p><input type="checkbox"/> Information available but only partially available in the BCH</p> <p><input checked="" type="checkbox"/> Information not available</p>
<p>g. Notifications regarding the release under your country's jurisdiction that leads, or may lead, to an unintentional transboundary movement of a LMO that is likely to have significant adverse effects on biological diversity (Article 17, paragraph 1)</p>	<p><input type="checkbox"/> Information available and in the BCH</p> <p><input type="checkbox"/> Information available but not in the BCH</p> <p><input type="checkbox"/> Information available but only partially available in the BCH</p> <p><input checked="" type="checkbox"/> Information not available</p>
<p>h. Information concerning cases of illegal transboundary movements of LMOs (Article 25, paragraph 3)</p>	<p><input type="checkbox"/> Information available and in the BCH</p> <p><input type="checkbox"/> Information available but not in the BCH</p> <p><input type="checkbox"/> Information available but only partially available in the BCH</p> <p><input checked="" type="checkbox"/> Information not available</p>
<p>i. Decisions regarding the importation of LMOs for intentional introduction into the environment (Article 10, paragraph 3)</p>	<p><input type="checkbox"/> Information available and in the BCH</p> <p><input type="checkbox"/> Information available but not in the BCH</p> <p><input type="checkbox"/> Information available but only partially available in the BCH</p> <p><input checked="" type="checkbox"/> Information not available</p>
<p>j. Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4)</p>	<p><input type="checkbox"/> Information available and in the BCH</p> <p><input type="checkbox"/> Information available but not in the BCH</p> <p><input type="checkbox"/> Information available but only partially available in the BCH</p> <p><input checked="" type="checkbox"/> Information not available</p>
<p>k. Decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1)</p>	<p><input type="checkbox"/> Information available and in the BCH</p> <p><input type="checkbox"/> Information available but not in the BCH</p> <p><input type="checkbox"/> Information available but only partially</p>

	<input checked="" type="checkbox"/> available in the BCH <input checked="" type="checkbox"/> Information not available
<p>i. Decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with Annex III to the Protocol (Article 11, paragraph 6)</p>	<input type="checkbox"/> Information available and in the BCH <input type="checkbox"/> Information available but not in the BCH <input type="checkbox"/> Information available but only partially available in the BCH <input checked="" type="checkbox"/> Information not available
<p>m. Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6)</p>	<input type="checkbox"/> Information available and in the BCH <input type="checkbox"/> Information available but not in the BCH <input type="checkbox"/> Information available but only partially available in the BCH <input checked="" type="checkbox"/> Information not available
<p>n. Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1)</p>	<input type="checkbox"/> Information available and in the BCH <input type="checkbox"/> Information available but not in the BCH <input type="checkbox"/> Information available but only partially available in the BCH <input checked="" type="checkbox"/> Information not available
<p>o. Cases where intentional transboundary movement may take place at the same time as the movement is notified to the Party of import (Article 13, paragraph 1 (a))</p>	<input type="checkbox"/> Information available and in the BCH <input type="checkbox"/> Information available but not in the BCH <input type="checkbox"/> Information available but only partially available in the BCH <input checked="" type="checkbox"/> Information not available
<p>p. LMOs granted exemption status by each Party (Article 13, paragraph 1 (b))</p>	<input type="checkbox"/> Information available and in the BCH <input type="checkbox"/> Information available but not in the BCH <input type="checkbox"/> Information available but only partially available in the BCH <input checked="" type="checkbox"/> Information not available
<p>q. Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3 (c))</p>	<input type="checkbox"/> Information available and in the BCH <input type="checkbox"/> Information available but not in the BCH <input type="checkbox"/> Information available but only partially available in the BCH <input checked="" type="checkbox"/> Information not available
<p>113. Please provide a brief explanation if you answered that the information is available <i>but not in the BCH</i> or <i>only partially available in the BCH</i> to any item under question 112:</p> <p>Palestinian Biosafety Clearing House Mechanism is under development. The emerging information related to GMOs/LMOs and products thereof would be submitted after getting an access for the Pal-BCH. Sharing this</p>	

<p>information with all related stakeholders will be facilitated. Indeed, the stakeholders have been introduced to the BCH website in one of the biosafety workshops organized as part of developing the NBF. The existing biosafety legislations and regulations, the proposed by-law on biosafety as well as the focal point contact details are part of the established NBF which will be submitted to the BCH upon getting an access.</p>	
<p>114. Has your country established a mechanism for strengthening the capacity of the BCH national focal point to perform its administrative functions?</p>	<p><input type="checkbox"/> Yes <input type="checkbox"/> Yes, to some extent: [Please specify] <input checked="" type="checkbox"/> No</p>
<p>115. Has your country established a mechanism for the coordination among the BCH national focal point, the Cartagena Protocol national focal point, and the competent national authority(ies) for making information available to the BCH?</p>	<p><input type="checkbox"/> Yes <input type="checkbox"/> Yes, to some extent: [Please specify] <input checked="" type="checkbox"/> No</p>
<p>116. Does your country use the information available in the BCH in its decision-making processes on LMOs?</p>	<p><input type="checkbox"/> Yes, always <input type="checkbox"/> Yes, in some cases <input type="checkbox"/> No <input checked="" type="checkbox"/> Not applicable (no decisions were taken)</p>
<p>117. Has your country experienced difficulties accessing or using the BCH?</p>	<p><input checked="" type="checkbox"/> Yes: we still do not have access to it <input type="checkbox"/> No</p>
<p>118. In the current reporting period, how many biosafety-related events (e.g. seminars, workshops, press conferences, educational events) has your country organized?</p>	<p><input type="checkbox"/> None <input checked="" type="checkbox"/> 1 to 4 <input type="checkbox"/> 5 to 9 <input type="checkbox"/> 10 to 24 <input type="checkbox"/> 25 or more</p>
<p>119. In the current reporting period, how many biosafety-related publications has your country published?</p>	<p><input checked="" type="checkbox"/> None <input type="checkbox"/> 1 to 9 <input type="checkbox"/> 10 to 49 <input type="checkbox"/> 50 to 99 <input type="checkbox"/> 100 or more</p>
<p>120. Here you may provide further details on the implementation of Article 20 in your country:</p> <p>The developing NBF includes proposed mechanism of regional harmonization of biosafety implementation in Palestine and the sub-regional countries. The harmonization mechanisms emphasize the role of establishing a national BCH and the coordination among the BCH, the focal point following CPB.</p>	
<p>Article 21 – Confidential information</p>	
<p>121. Has your country established procedures to protect confidential information received</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> Yes, to some extent: Proposed in the NBF</p>

under the Protocol?	<input type="checkbox"/> No
122. Does your country allow the notifier to identify information that is to be treated as confidential?	<input type="checkbox"/> Yes, always <input checked="" type="checkbox"/> In some cases only <input type="checkbox"/> No
123. Here you may provide further details on the implementation of Article 21 in your country: The proposed by-law, Article 3, paragraph 6 states that certain items of the applicants will be confidential following a written request by the applicant and approval by the EQA. Other information, defined in the bi-law, cannot be treated as confidential under any case. If the applicant has a reasonable justification to identify information that is to be treated as confidential, the responsible authorities (EQA, NBC, focal point) will approve his formal request. The confidential information will not be shared with irrelevant individuals or organizations.	
Article 22 – Capacity-building	
124. Does your country have predictable and reliable funding for building capacity for the effective implementation of the Protocol?	<input type="checkbox"/> Yes <input type="checkbox"/> Yes, to some extent: [Please specify] <input checked="" type="checkbox"/> No
125. Has your country received external support or benefited from collaborative activities with other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?	<input type="checkbox"/> Yes <input type="checkbox"/> Yes, to some extent: [Please specify] <input checked="" type="checkbox"/> No
126. If you answered <i>Yes</i> to question 125, how were these resources made available?	<input type="checkbox"/> Bilateral channels <input type="checkbox"/> Regional channels <input type="checkbox"/> Multilateral channels
127. Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?	<input type="checkbox"/> Yes <input type="checkbox"/> Yes, to some extent: [Please specify] <input checked="" type="checkbox"/> No
128. If you answered <i>Yes</i> to question 127, how were these resources made available?	<input type="checkbox"/> Bilateral channels <input type="checkbox"/> Regional channels <input type="checkbox"/> Multilateral channels
129. In the reporting period, has your country initiated a process to access funds from the Global Environment Facility (GEF) for building capacity in biosafety?	<input type="checkbox"/> Yes: [Please specify] <input checked="" type="checkbox"/> No
130. If you answered <i>Yes</i> to question 129, how would you characterize the process?	<input type="checkbox"/> Very easy <input type="checkbox"/> Easy <input type="checkbox"/> Average <input type="checkbox"/> Difficult

	<input type="checkbox"/> Very difficult
<p>131. In the current reporting period, has your country undertaken activities for the development and/or strengthening of human resources and institutional capacities in biosafety?</p>	<input type="checkbox"/> Yes <input type="checkbox"/> Yes, to some extent: [Please specify] <input checked="" type="checkbox"/> No
<p>132. If you answered <i>Yes</i> to question 131, in which of the following areas were these activities undertaken (select all that apply)?</p>	<input type="checkbox"/> Institutional capacity and human resources <input type="checkbox"/> Integration of biosafety in cross-sectoral and sectoral legislation, policies and institutions (mainstreaming biosafety) <input type="checkbox"/> Risk assessment and other scientific and technical expertise <input type="checkbox"/> Risk management <input type="checkbox"/> Public awareness, participation and education in biosafety <input type="checkbox"/> Information exchange and data management, including participation in the Biosafety Clearing-House <input type="checkbox"/> Scientific, technical and institutional collaboration at subregional, regional and international levels <input type="checkbox"/> Technology transfer <input type="checkbox"/> Identification of LMOs, including their detection <input type="checkbox"/> Socioeconomic considerations <input type="checkbox"/> Implementation of the documentation requirements under Article 18.2 of the Protocol <input type="checkbox"/> Handling of confidential information <input type="checkbox"/> Measures to address unintentional and/or illegal transboundary movements of LMOs <input type="checkbox"/> Scientific biosafety research relating to LMOs <input type="checkbox"/> Taking into account risks to human health <input type="checkbox"/> Liability and redress <input type="checkbox"/> Other: [Please specify]
<p>133. In the current reporting period, has your country carried out a capacity-building needs assessment?</p>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<p>134. Does your country still have capacity-building needs?</p>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<p>135. If you answered <i>Yes</i> to question 134, which of the following areas still need capacity-building (select all that apply)?</p>	<input checked="" type="checkbox"/> Institutional capacity and human resources <input checked="" type="checkbox"/> Integration of biosafety in cross-sectoral and sectoral legislation, policies and institutions (mainstreaming biosafety) <input checked="" type="checkbox"/> Risk assessment and other scientific and technical expertise <input checked="" type="checkbox"/> Risk management <input checked="" type="checkbox"/> Public awareness, participation and education in biosafety

	<input checked="" type="checkbox"/> Information exchange and data management, including participation in the Biosafety Clearing-House <input checked="" type="checkbox"/> Scientific, technical and institutional collaboration at subregional, regional and international levels <input checked="" type="checkbox"/> Technology transfer <input checked="" type="checkbox"/> Sampling, detection and identification of LMOs <input checked="" type="checkbox"/> Socioeconomic considerations <input checked="" type="checkbox"/> Implementation of the documentation requirements for handling, transport, packaging and identification <input checked="" type="checkbox"/> Handling of confidential information <input checked="" type="checkbox"/> Measures to address unintentional and/or illegal transboundary movements of LMOs <input checked="" type="checkbox"/> Scientific biosafety research relating to LMOs <input checked="" type="checkbox"/> Taking into account risks to human health <input checked="" type="checkbox"/> Liability and redress <input type="checkbox"/> Other: [Please specify]
<p>136. Has your country developed a capacity-building strategy or action plan?</p>	<input checked="" type="checkbox"/> Yes proposed in the NBF <input type="checkbox"/> No
<p>137. Does your country have in place a functional national mechanism for coordinating biosafety capacity-building initiatives?</p>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<p>138. Here you may provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds:</p> <p>EQA applied for GEF funds for national reporting i.e. to prepare the fourth national report on biosafety and other reports and strategies like NBSAP to the CBD. For political reasons, the application has been rejected many times.</p>	

Article 23 – Public awareness and participation	
<p>139. Is biosafety public awareness, education and/or participation addressed in legislation or policy in your country?</p>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> Yes, to some extent: proposed action plan in the NBF and the awareness and capacity building of the NBF <input type="checkbox"/> No
<p>140. In the current reporting period, has your country cooperated with other States and international bodies in relation to public awareness, education and participation?</p>	<input type="checkbox"/> Yes: [Please specify] <input checked="" type="checkbox"/> No
<p>141. Has your country established a mechanism to ensure public access to information on LMOs?</p>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> Yes, to some extent: Proposed in the MBF <input type="checkbox"/> No

<p>142. Does your country have in place a national communication strategy on biosafety?</p>	<p><input type="checkbox"/> Yes: [Please specify] <input checked="" type="checkbox"/> No</p>
<p>143. Does your country have any awareness and outreach programmes on biosafety?</p>	<p><input type="checkbox"/> Yes: [Please specify] <input checked="" type="checkbox"/> No</p>
<p>144. Does your country currently have a national biosafety website?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>145. How many academic institutions in your country are offering biosafety education and training courses and programmes?</p>	<p><input type="checkbox"/> None <input checked="" type="checkbox"/> 1 to 4 <input type="checkbox"/> 5 to 9 <input type="checkbox"/> 10 or more</p> <p><i>Is this number adequate:</i> <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>146. How many educational materials and/or online modules on biosafety are available and accessible to the public in your country?</p>	<p><input checked="" type="checkbox"/> None <input type="checkbox"/> 1 to 4 <input type="checkbox"/> 5 to 9 <input type="checkbox"/> 10 to 24 <input type="checkbox"/> 25 to 99 <input type="checkbox"/> 100 or more</p> <p><i>Is this number adequate:</i> <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>147. Has your country established a mechanism to consult the public in the decision-making process regarding LMOs?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> Yes, to some extent: Proposed in the NBF <input type="checkbox"/> No</p>
<p>148. Has your country informed the public about existing modalities for public participation in the decision-making process regarding LMOs?</p>	<p><input type="checkbox"/> Yes <input type="checkbox"/> Yes, to some extent: [Please specify] <input checked="" type="checkbox"/> No</p>
<p>149. If you answered <i>Yes</i> to question 148, please indicate the modalities used to inform the public:</p>	<p><input type="checkbox"/> National websites <input type="checkbox"/> Newspapers <input type="checkbox"/> Forums <input type="checkbox"/> Mailing lists <input type="checkbox"/> Public hearings <input type="checkbox"/> Social media <input type="checkbox"/> Other: [Please specify] EQA website</p>

<p>150. In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs?</p>	<p><input type="checkbox"/> None (decisions taken without consultation) <input type="checkbox"/> 1 to 4 <input type="checkbox"/> 5 or more <input checked="" type="checkbox"/> Not applicable (no decisions were taken)</p>
<p>151. Has your country informed the public about the means to access the Biosafety Clearing-House?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>152. Here you may provide further details on the implementation of Article 23 in your country: Mechanisms for the public participation and education has have been proposed in the NBF</p>	
<p>Article 24 – Non-Parties</p>	
<p>153. Has your country entered into any bilateral, regional, or multilateral agreement with non-Parties regarding transboundary movements of LMOs?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>154. In the current reporting period, has your country imported LMOs from a non-Party?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>155. In the current reporting period, has your country exported LMOs to a non-Party?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>156. If you answered <i>Yes</i> to question 154 and/or 155, were the transboundary movements of LMOs consistent with the objective of the Cartagena Protocol on Biosafety?</p>	<p><input type="checkbox"/> Yes, always <input type="checkbox"/> In some cases only <input type="checkbox"/> No</p>
<p>157. Here you may provide further details on the implementation of Article 24 in your country: [Type your text here]</p>	
<p>Article 25 – Illegal transboundary movements³</p>	
<p>158. Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement the Cartagena Protocol?</p>	<p><input type="checkbox"/> Yes <input type="checkbox"/> Yes, to some extent: [Please specify] <input checked="" type="checkbox"/> No</p>

³ In accordance with the operational definition adopted in decision CP VIII/16, “‘Illegal transboundary movement’ is a transboundary movement of living modified organisms carried out in contravention of the domestic measures to implement the Protocol that have been adopted by the Party concerned”.

<p>159. In the current reporting period, how many cases of illegal transboundary movements of LMOs has your country become aware of?</p>	<p><input checked="" type="checkbox"/> None <input type="checkbox"/> 1 to 4 <input type="checkbox"/> 5 to 9 <input type="checkbox"/> 10 or more</p>
<p>160. If you indicated <i>under question 159</i> that <i>your country became aware of cases of illegal transboundary movements</i>, has the origin of the LMO(s) been established?</p>	<p><input type="checkbox"/> Yes <input type="checkbox"/> Yes, some cases <input type="checkbox"/> No</p>
<p>161. Here you may provide further details on the implementation of Article 25 in your country: IN Palestine we don't have the capacity to identify LMO's at the Borders , therefore illegall transboundary movements might not be detected, capacity building mechanisms have been proposed in the NBF</p>	
<p>Article 26 – Socio-economic considerations</p>	
<p>162. Does your country have any specific approaches or requirements that facilitate how socioeconomic considerations should be taken into account in LMO decision-making?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>163. In the current reporting period, have socioeconomic considerations arising from the impact of LMOs been taken into account in decision-making?</p>	<p><input type="checkbox"/> Yes, always <input type="checkbox"/> In some cases only <input type="checkbox"/> No <input checked="" type="checkbox"/> Not applicable (no decisions were taken)</p>
<p>164. How many peer-reviewed published materials has your country used for the purpose of elaborating or determining national actions with regard to socioeconomic considerations?</p>	<p><input checked="" type="checkbox"/> None <input type="checkbox"/> 1 to 4 <input type="checkbox"/> 5 to 9 <input type="checkbox"/> 10 to 49 <input type="checkbox"/> 50 or more</p> <p><i>Is this number adequate:</i> <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>165. Has your country cooperated with other Parties on research and information exchange on any socioeconomic impacts of LMOs?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>166. Here you may provide further details on the implementation of Article 26 in your country: [Type your text here]</p>	

Article 28 – Financial mechanism and resources	
167. In the current reporting period, how much funding (in the equivalent of US dollars) has your country mobilized to support implementation of the Cartagena Protocol beyond the regular national budgetary allocation?	<input type="checkbox"/> Nothing <input type="checkbox"/> 1 to 4,999 USD <input type="checkbox"/> 5,000 to 49,999 USD <input checked="" type="checkbox"/> 50,000 to 99,999 USD <input type="checkbox"/> 100,000 to 499,000 USD <input type="checkbox"/> 500,000 USD or more
Article 33 – Monitoring and reporting	
<i>Article 33 requires Parties to monitor <u>the implementation of its obligations</u> under the Cartagena Protocol and to report to the Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol on measures taken to implement the Protocol</i>	
168. Does your country have in place a system to monitor and enforce the implementation of the Cartagena Protocol?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress	
<i>Parties to the Cartagena Protocol that are not yet Party to the Supplementary Protocol are also invited to respond to the questions below</i>	
169. Is your country a Party to the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
170. If you answered <i>No</i> to question 169, is there any national process in place towards becoming a Party to the Supplementary Protocol?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
171. Has your country introduced the necessary measures for the implementation of the Supplementary Protocol?	<input type="checkbox"/> National measures are fully in place <input type="checkbox"/> National measures are partially in place <input type="checkbox"/> Only temporary measures have been introduced <input type="checkbox"/> Only draft measures exist <input checked="" type="checkbox"/> No measures have yet been taken
172. Which instruments are in place for the implementation of the Supplementary Protocol?	<input type="checkbox"/> One or more national laws: [Please specify] <input type="checkbox"/> One or more national regulations: [Please specify] <input type="checkbox"/> One or more sets of guidelines: [Please specify] <input checked="" type="checkbox"/> No instruments are in place
173. Does your country have administrative or legal instruments that require response measures to be taken:	

<p>a. In case of damage resulting from LMOs?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>b. In case there is sufficient likelihood that damage will result if response measures are not taken?</p>	<p><input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>174. If you answered <i>Yes</i> to question 173a, do these instruments impose requirements on an operator (select all that apply)?</p>	<p><input type="checkbox"/> Yes, the operator must inform the competent authority of the damage <input type="checkbox"/> Yes, the operator must evaluate the damage <input type="checkbox"/> Yes, the operator must take response measures <input type="checkbox"/> Yes, other requirements: [Please specify] <input type="checkbox"/> No</p>
<p>175. If you answered <i>Yes</i> to question 173a, do these instruments require the operator to take response measures to avoid damage?</p>	<p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>176. If you answered <i>Yes</i> to question 173a or 173b, do these instruments provide for a definition of “operator”?</p>	<p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>177. If you answered <i>Yes</i> to question 176, which of the following could be an ‘operator’ (select all that apply)?</p>	<p><input type="checkbox"/> Permit holder <input type="checkbox"/> Person who placed the LMO on the market <input type="checkbox"/> Developer <input type="checkbox"/> Producer <input type="checkbox"/> Notifier <input type="checkbox"/> Exporter <input type="checkbox"/> Importer <input type="checkbox"/> Carrier <input type="checkbox"/> Supplier <input type="checkbox"/> Other: [Please specify]</p>
<p>178. Has a competent authority been identified for carrying out the functions set out in the Supplementary Protocol?</p>	<p><input type="checkbox"/> Yes: [Please specify] <input checked="" type="checkbox"/> No</p>

<p>179. If you answered <i>Yes</i> to question 178, what measures may the competent authority take (select all that apply)?</p>	<p><input type="checkbox"/> Identify the operator that caused the damage</p> <p><input type="checkbox"/> Evaluate the damage</p> <p><input type="checkbox"/> Determine response measures to be taken by operator</p> <p><input type="checkbox"/> Implement response measures</p> <p><input type="checkbox"/> Recover costs and expenses of the evaluation of the damage and the implementation of any response measures from the operator</p> <p><input type="checkbox"/> Other: [Please specify]</p>
<p>180. Does your country have measures in place to provide for financial security for damage resulting from LMOs?</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p>
<p>181. If you answered <i>Yes</i> to question 180, what type of financial security measures are in place (select all that apply)?</p>	<p><input type="checkbox"/> Requirement to provide evidence for secure source of funding</p> <p><input type="checkbox"/> Mandatory insurance</p> <p><input type="checkbox"/> Government schemes, including funds</p> <p><input type="checkbox"/> Other: [Please specify]</p>
<p>182. Does your country have rules and procedures on civil liability that address damage resulting from LMOs, or has such damage been recognized in court rulings (select all that apply)?</p>	<p><input type="checkbox"/> Yes, in a civil liability instrument</p> <p><input type="checkbox"/> Yes, in court rulings</p> <p><input type="checkbox"/> Yes, in other instruments: [Please specify]</p> <p><input checked="" type="checkbox"/> No</p>
<p>183. Have there been any occurrences of damage resulting from LMOs in your country?</p>	<p><input type="checkbox"/> Yes: [Please specify]</p> <p><input checked="" type="checkbox"/> No</p>
<p>184. If you answered <i>Yes</i> to question 183, have response measures been taken?</p>	<p><input type="checkbox"/> Yes: [Please specify]</p> <p><input type="checkbox"/> No</p>
<p>185. Here you may provide further details on any activities undertaken in your country towards the implementation of the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress:</p> <p>[Type your text here]</p>	
<p style="text-align: center;">Other information</p>	
<p>186. Please use this field to provide any other information on issues related to national implementation of the Cartagena Protocol and the Supplementary Protocol, including any obstacles or impediments encountered.</p> <p>Lack of financial resources mainly from GEF to implement the proposals of the developing NBF and to implement the CPB, and the lack of adequate number of national experts mainly in the field of risk assessment and management.</p>	

Comments on reporting format

187. Please use this field to provide any other information on difficulties that you have encountered in filling in this report.

We did not have an access to the online reporting tool. We requested one from the secretariat of the BCH. Until now, we did not receive an access. Therefore, we prepared the fourth national report on biosafety on a Microsoft word template. The BCH secretariat should provide prompt and reasonable justification of the delay in providing the state of Palestine, who is a signed member of the CBD/CPB, such an access.